New hope for tough cancers: first human test of targeted drug begins

NCT ID NCT03993873

Summary

This is an early-stage study to test a new oral drug called TPX-0022 (elzovantinib) in adults with advanced or spreading cancers that have specific changes in a gene called MET. The main goals are to find a safe dose, see how the body processes the drug, and get a first look at whether it can shrink or control tumors. The study will include people with certain types of lung cancer, stomach cancer, or other solid tumors that have these MET alterations.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Local Institution - 2101

    Houston, Texas, 77030-4009, United States

  • Local Institution - 2102

    La Jolla, California, 92093, United States

  • Local Institution - 2103

    St Louis, Missouri, 63110, United States

  • Local Institution - 2104

    Toledo, Ohio, 43614, United States

  • Local Institution - 2105

    Denver, Colorado, 80218, United States

  • Local Institution - 2106

    Ann Arbor, Michigan, 48109, United States

  • Local Institution - 2107

    Boston, Massachusetts, 02114, United States

  • Local Institution - 2108

    Orange, California, 92868, United States

  • Local Institution - 2109

    Boston, Massachusetts, 02215, United States

  • Local Institution - 2111

    Chicago, Illinois, 60637, United States

  • Local Institution - 2112

    Fairfax, Virginia, 22031, United States

  • Local Institution - 2113

    Detroit, Michigan, 48202, United States

  • Local Institution - 4101

    Madrid, 28050, Spain

  • Local Institution - 4102

    Pamplona, 31008, Spain

  • Local Institution - 4103

    Madrid, 28040, Spain

  • Local Institution - 4104

    Madrid, 28036, Spain

  • Local Institution - 4201

    Lyon, 69008, France

  • Local Institution - 4202

    La Tronche, Auvergne-Rhône-Alpes, 38700, France

  • Local Institution - 4203

    Saint-Mandé, Val-de-Marne, 94160, France

  • Local Institution - 4204

    Villejuif, Val-de-Marne, 94805, France

  • Local Institution - 6301

    Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea

  • Local Institution - 6302

    Seoul, 120-752, South Korea

  • Local Institution - 6303

    Seoul, 03080, South Korea

  • Local Institution - 6304

    Seoul, 05505, North Korea

Conditions

Explore the condition pages connected to this study.